Immunomodulating Compositions and uses Therefor
First Claim
1. A composition for modulating an immune response to a target antigen, comprising a lectin-interactive agent and an immune-modulating agent selected from the group consisting of an antigen that corresponds to at least a portion of the target antigen, an antigen-binding molecule that is immuno-interactive with the target antigen and an immune-modulating cell that modulates an immune response to the target antigen.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention discloses immunomodulating compositions. More particularly, the present invention discloses compositions comprising an immune-modulating agent and a lectin-interactive agent, which are useful for stimulating and prolonging host immune cell responses. The compositions of the present invention are particularly useful in the treatment and/or prophylaxis of a range of conditions including pathogenic infections, autoimmune diseases, transplant rejection, graft versus host disease, allergies, inflammatory disease, as well as cancers and tumours.
-
Citations
64 Claims
- 1. A composition for modulating an immune response to a target antigen, comprising a lectin-interactive agent and an immune-modulating agent selected from the group consisting of an antigen that corresponds to at least a portion of the target antigen, an antigen-binding molecule that is immuno-interactive with the target antigen and an immune-modulating cell that modulates an immune response to the target antigen.
- 46. A method for modulating an immune response to a target antigen in a subject, comprising administering to the subject a composition comprising a lectin-interactive agent and an immune-modulating agent selected from the group consisting of an antigen that corresponds to at least a portion of the target antigen, an antigen-binding molecule that is immuno-interactive with the target antigen and an immune-modulating cell that modulates an immune response to the target antigen.
-
53. Use of a lectin-interactive agent and an immune-modulating agent in the manufacture of a medicament for modulating an immune response to a target antigen, wherein the immune-modulating agent is selected from group consisting of an antigen that corresponds to at least a portion of the target antigen, an antigen-binding molecule that is immuno-interactive with the target antigen and an immune-modulating cell that modulates an immune response to the target antigen.
-
54. Use of a lectin-interactive agent and an immune-modulating agent in the manufacture of a medicament for treating or preventing a disease or condition associated with the presence or aberrant expression of a target antigen, wherein the immune-modulating agent is selected from group consisting of an antigen that corresponds to at least a portion of the target antigen, an antigen-binding molecule that is immuno-interactive with the target antigen and an immune-modulating cell that modulates an immune response to the target antigen.
-
55. A method for identifying a lectin-interactive agent, comprising (a) culturing a first sample of a population of immune effector cells in the presence of a first sample of a lectin-expressing cell or pathogen;
- (b) culturing a second sample of the population in the presence of a second sample of the lectin-expressing cell or pathogen and a candidate agent suspected of having lectin-interaction activity, and (c) quantifying the immune effector cells in the first and second samples, respectively, whereby an increase in the number of immune effector cells in the second sample as compared to the first sample indicates that the candidate agent is a lectin-interactive agent.
- View Dependent Claims (56, 57, 58, 59, 60, 61)
-
62. A method for assaying the activity of a lectin-interactive agent, comprising (a) culturing a first sample of a population of immune effector cells in the presence of a first sample of a lectin-expressing cell or pathogen;
- (b) culturing a second sample of the population in the presence of a second sample of the lectin-expressing cell or pathogen and a lectin-interactive agent, and (c) quantifying the immune effector cells in the first and second samples, respectively.
- View Dependent Claims (63, 64)
Specification